164 related articles for article (PubMed ID: 17257495)
21. Comparing two arsenic trioxide administration methods in APL therapy.
Zhou J; Meng R; Yang BF
Chin Med J (Engl); 2004 Sep; 117(9):1411-3. PubMed ID: 15377438
[No Abstract] [Full Text] [Related]
22. Changes in microrheology of acute promyelocytic leukemia cells during all-trans retinoic acid (ATRA) differentiation therapy: a mechanism for ATRA-induced hyperleukocytosis?
Dombret H; Geiger S; Daniel MT; Glaisner S; Micléa JM; Castaigne S; Merle-Beral H; Lacombe C; Chomienne C; Degos L
Leukemia; 1995 Sep; 9(9):1473-7. PubMed ID: 7658714
[TBL] [Abstract][Full Text] [Related]
23. The relationship between the levels of granulocyte colony-stimulating factor and leukocytosis induced by all-trans retinoic acid in acute promyelocytic leukemia.
Wu W; Sun G; Wu W; Zhou R; Li X; Shen Z; Wang Z
Chin Med J (Engl); 1999 Dec; 112(12):1085-7. PubMed ID: 11721444
[TBL] [Abstract][Full Text] [Related]
24. Use of all-trans retinoic acid in combination with arsenic trioxide for remission induction in patients with newly diagnosed acute promyelocytic leukemia and for consolidation/maintenance in CR patients.
Dai CW; Zhang GS; Shen JK; Zheng WL; Pei MF; Xu YX; Cao YX; Yi Y; Yang JJ; Peng HL; Zhong HY; Li RJ
Acta Haematol; 2009; 121(1):1-8. PubMed ID: 19246888
[TBL] [Abstract][Full Text] [Related]
25. [Coagulopathy and differentiation syndrome: the main complications of the initial treatment of acute promyelocytic leukemia].
Korístek Z; Zák P
Vnitr Lek; 2008; 54(7-8):745-50. PubMed ID: 18780573
[TBL] [Abstract][Full Text] [Related]
26. Leukocytosis and retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide.
Jin B; Hou KZ; Liu YP; Yu P
Chin Med Sci J; 2006 Sep; 21(3):171-4. PubMed ID: 17086739
[TBL] [Abstract][Full Text] [Related]
27. The expanding role of arsenic in acute promyelocytic leukemia.
Tallman MS
Semin Hematol; 2008 Jul; 45(3 Suppl 2):S25-9. PubMed ID: 18760708
[TBL] [Abstract][Full Text] [Related]
28. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
[TBL] [Abstract][Full Text] [Related]
29. Requirement for myeloid growth factors in the differentiation of acute promyelocytic leukaemia.
Matsui W; Smith BD; Vala M; Beal N; Huff CA; Diehl LF; Jones RJ
Br J Haematol; 2005 Mar; 128(6):853-62. PubMed ID: 15755292
[TBL] [Abstract][Full Text] [Related]
30. [The impact of arsenic trioxide or all-trans retinoic acid treatment on coagulopathy in acute promyelocytic leukemia].
Zhang X; Zhou H; Song S; Qiao Z; Yang L; Hu Y
Zhonghua Nei Ke Za Zhi; 2001 Dec; 40(12):829-33. PubMed ID: 16206674
[TBL] [Abstract][Full Text] [Related]
31. Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence.
Sanz MA; Fenaux P; Lo Coco F;
Haematologica; 2005 Sep; 90(9):1231-5. PubMed ID: 16154847
[TBL] [Abstract][Full Text] [Related]
32. [Fatal side-effects of all-trans retinoic acid in the treatment of acute promyelocytic leukemia].
Yang J; Han Z; Pei M; Xiao N
Hunan Yi Ke Da Xue Xue Bao; 1999; 24(3):293-5. PubMed ID: 12016812
[TBL] [Abstract][Full Text] [Related]
33. Arsenic trioxide.
Wilkinson K
Clin J Oncol Nurs; 2001; 5(5):237-8. PubMed ID: 11899773
[No Abstract] [Full Text] [Related]
34. Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement.
Knipp S; Gattermann N; Schapira M; Käferstein H; Germing U
Leuk Res; 2007 Nov; 31(11):1585-7. PubMed ID: 17416415
[TBL] [Abstract][Full Text] [Related]
35. Programmed cell death-4 tumor suppressor protein contributes to retinoic acid-induced terminal granulocytic differentiation of human myeloid leukemia cells.
Ozpolat B; Akar U; Steiner M; Zorrilla-Calancha I; Tirado-Gomez M; Colburn N; Danilenko M; Kornblau S; Berestein GL
Mol Cancer Res; 2007 Jan; 5(1):95-108. PubMed ID: 17259349
[TBL] [Abstract][Full Text] [Related]
36. [Drug resistance of acute promyelocytic leukemia (APL) to all-trans retinoic acid (ATRA) and its reversion].
Jiang G; Tang T; Bi K
Zhonghua Zhong Liu Za Zhi; 2000 Mar; 22(2):154-7. PubMed ID: 11776647
[TBL] [Abstract][Full Text] [Related]
37. Anion exchanger 2 mediates the action of arsenic trioxide.
Pan XY; Chen GQ; Cai L; Buscemi S; Fu GH
Br J Haematol; 2006 Sep; 134(5):491-9. PubMed ID: 17018029
[TBL] [Abstract][Full Text] [Related]
38. Acute promyelocytic leukemia: new issues on pathogenesis and treatment response.
Vitoux D; Nasr R; de The H
Int J Biochem Cell Biol; 2007; 39(6):1063-70. PubMed ID: 17468032
[TBL] [Abstract][Full Text] [Related]
39. The effect of arsenic trioxide on QT interval prolongation during APL therapy.
Zhou J; Meng R; Li X; Lu C; Fan S; Yang B
Chin Med J (Engl); 2003 Nov; 116(11):1764-6. PubMed ID: 14642155
[TBL] [Abstract][Full Text] [Related]
40. Acute promyelocytic leukemia: recent advances in diagnosis and management.
Lo-Coco F; Ammatuna E; Montesinos P; Sanz MA
Semin Oncol; 2008 Aug; 35(4):401-9. PubMed ID: 18692690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
